Landmark trial
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Brown PD, Gondi V, Pugh S, et al. · NRG Oncology
DoseLab summary
Phase 3 trial of 518 patients with brain metastases randomized to whole-brain radiotherapy with or without hippocampal avoidance, both with memantine. Hippocampal avoidance lowered the risk of cognitive failure with no difference in survival or intracranial control. Citation checked against Crossref.
Why this is useful
The trial that made hippocampal avoidance a standard option when whole-brain treatment is given to patients with a good prognosis.
Reference details
- Title
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
- Authors / organization
- Brown PD, Gondi V, Pugh S, et al. · NRG Oncology
- Publication / protocol
- J Clin Oncol. 2020;38(10):1019–1029
- Version
- Pending verification
- Year
- 2020
- DOI
- 10.1200/JCO.19.02767
- Disease sites
- CNS / Brain
- Topics
- Whole brain, Hippocampal avoidance, Brain metastases, Landmark trial
- Fractionation context
- 30 Gy / 10 fx
- Last reviewed by DoseLab
- Pending verification